May. 21 at 9:45 PM
$FLGT "FID-007, administered in combination with cetuximab, demonstrated clinically encouraging and durable anticancer activity at both doses tested in this population of pre-treated R/M HNSCC. Notably, the absence of infusion-related reactions and the lack of grade ≥ 3 PN, along with a tolerable safety profile potentially compares favorably with other taxanes, which may ultimately enable a longer treatment duration and lead to improved therapeutic outcomes."
https://www.asco.org/abstracts-presentations/261444
